[go: up one dir, main page]

AR116566A1 - Administración sostenida de polipéptidos similares a la angiopoyetina 3 - Google Patents

Administración sostenida de polipéptidos similares a la angiopoyetina 3

Info

Publication number
AR116566A1
AR116566A1 ARP190102781A ARP190102781A AR116566A1 AR 116566 A1 AR116566 A1 AR 116566A1 AR P190102781 A ARP190102781 A AR P190102781A AR P190102781 A ARP190102781 A AR P190102781A AR 116566 A1 AR116566 A1 AR 116566A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydrogen
optionally substituted
cycloalkyl
drug delivery
Prior art date
Application number
ARP190102781A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR116566A1 publication Critical patent/AR116566A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En este documento, se describen sistemas de administración de fármacos para administrar agentes biológicamente activos que comprenden aminas primarias o secundarias, o un átomo de nitrógeno de anillo de un anillo azaheteroarilo, sales farmacéuticamente aceptables de los mismos, reactivos de administración de fármacos relacionados con el mismo, composiciones farmacéuticas que comprenden los sistemas de administración de fármacos y el uso de los sistemas de administración de fármacos como terapéutica de liberación sostenida. Reivindicación 1: Un sistema de administración de fármacos o una sal farmacéuticamente aceptable del mismo que comprende D-R, que está representado por la fórmula (1), en donde D comprende un polipéptido ANGPTL3 que comprende al menos una amina primaria; y R es un enlazador adecuado para la liberación de D, donde la línea de puntos indica unión con la amina primaria; R¹ es hidrógeno o alquilo C₁₋₄; R¹ᵃ es hidrógeno o alquilo C₁₋₄, o CR¹R¹ᵃ, tomados en combinación, forman un cicloalq C₃₋₆-1,1-diílo; R² se selecciona, de modo independiente, en cada aparición, de alquilo C₁₋₄ u oxo, o dos grupos R² tomados en combinación con los átomos de carbono a los que están unidos, forman un grupo cicloalquilo C₃₋₆ fusionado o grupo espirocicloalq C₃₋₆-1,1-diílo; a es 0, 1, 2, 3 ó 4; R³ es hidrógeno o alquilo C₁₋₄; R³ᵃ es hidrógeno, alquilo C₁₋₄, o CR³R³ᵃ tomados en combinación, forman un cicloalq C₃₋₆-1,1-diílo; Y es C(O)R⁴, C(O)OR⁴, C(O)NHR⁴, C(O)NR⁵R⁶, SiR⁵R⁶R⁷, o CR¹²R¹²ᵃOR¹³; R¹² es hidrógeno o alquilo C₁₋₄; R¹²ᵃ es hidrógeno o alquilo C₁₋₄, o CR¹²R¹²ᵃ, tomados en combinación, forman un cicloalq C₃₋₆-1,1-diílo; R¹³ es alquilo C₁₋₄; o R¹² y R¹³, tomados en combinación con C(R¹²ᵃ) y O forman un éter cíclico de 5, 6 ó 7 miembros; R⁴ es alquilo C₁₋₈ o cicloalquilo C₃₋₇, en donde el cicloalquilo está opcionalmente sustituido con 0, 1, ó 2 grupos alquilo C₁₋₄ seleccionados de modo independiente y en donde el alquilo está opcionalmente sustituido con alcoxi C₁₋₄; R⁵ y R⁶ se seleccionan cada uno, de modo independiente, de alquilo C₁₋₄ y cicloalquilo C₃₋₆; R⁷ es alquilo C₁₋₈, cicloalquilo C₃₋₇, alcoxi C₁₋₈, cicloalquiloxi C₃₋₇, heterocicloalquiloxi, u -(OCHR³CH₂)ᵇO-alquilo C₁₋₄, en donde el heterocicloalquiloxi es un anillo heterocíclico saturado de 4 a 7 miembros que tiene un heteroátomo del anillo seleccionado de N, O y S y opcionalmente sustituido con 0, 1, ó 2 grupos alquilo C₁₋₄ seleccionados de modo independiente; b es un número entero de 1 a 10; Z es CH-L-A, CH-A, N-L-A, o N-A; L es un enlazador bivalente opcionalmente sustituido; A es hidrógeno, alquilo C₁₋₈, C(O)alquilo C₁₋₈, C(O)N(H)alquilo C₁₋₈, C(O)O-alquilo C₁₋₈, R¹⁰, o R¹¹, en donde el grupo alquilo está opcionalmente sustituido con 0 ó 1 R¹⁰; R¹⁰ es un grupo funcional reactivo apropiado para acoplar la fórmula (1) a un portador; y R¹¹ es un portador.
ARP190102781A 2018-10-03 2019-10-01 Administración sostenida de polipéptidos similares a la angiopoyetina 3 AR116566A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862740609P 2018-10-03 2018-10-03

Publications (1)

Publication Number Publication Date
AR116566A1 true AR116566A1 (es) 2021-05-19

Family

ID=68165677

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102781A AR116566A1 (es) 2018-10-03 2019-10-01 Administración sostenida de polipéptidos similares a la angiopoyetina 3

Country Status (25)

Country Link
US (2) US11389541B2 (es)
EP (1) EP3860657A1 (es)
JP (2) JP7336513B2 (es)
KR (1) KR20210066860A (es)
CN (1) CN112770782A (es)
AR (1) AR116566A1 (es)
AU (1) AU2019353174A1 (es)
BR (1) BR112021005981A2 (es)
CA (1) CA3112251A1 (es)
CL (1) CL2021000819A1 (es)
CO (1) CO2021004012A2 (es)
CR (1) CR20210156A (es)
CU (1) CU20210022A7 (es)
DO (1) DOP2021000053A (es)
EA (1) EA202190650A1 (es)
EC (1) ECSP21022120A (es)
IL (1) IL281227A (es)
JO (1) JOP20210061A1 (es)
MX (1) MX2021003839A (es)
PE (1) PE20211646A1 (es)
PH (1) PH12021550675A1 (es)
SG (1) SG11202102076TA (es)
TW (1) TW202027794A (es)
WO (1) WO2020070675A1 (es)
ZA (1) ZA202101419B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113795590B (zh) * 2019-05-07 2024-11-26 建新公司 前药组合物中药物浓度的量化方法
CN112220963B (zh) * 2020-09-24 2022-05-24 哈尔滨工业大学 一种非溶胀uv交联壳聚糖可注射水凝胶及其合成方法
TW202306970A (zh) 2021-05-24 2023-02-16 瑞士商諾華公司 用於治療骨關節炎之方法
EP4346876A1 (en) 2021-05-24 2024-04-10 Novartis AG Methods for the treatment of osteoarthritis
JP2025531629A (ja) * 2022-08-23 2025-09-24 アステラス インスティテュート フォー リジェネレイティブ メディシン 細胞凍結保存製剤および使用方法
CN115970066B (zh) * 2022-12-29 2024-09-27 成都爱睿康乐医疗器械有限公司 基于主客体相互作用的载药纳米凝胶生物润滑剂及其制备方法和应用
WO2024240212A1 (zh) * 2023-05-24 2024-11-28 云合智药（苏州）生物科技有限公司 用于抑制angptl3表达的rnai剂及其应用
CN117379362B (zh) * 2023-10-11 2024-07-19 首都医科大学附属北京潞河医院 负载血管生成素样蛋白3的水凝胶及其制备方法与应用

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308236D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Dna vectors
DE3737523A1 (de) 1987-11-05 1989-05-18 Bayer Ag Verwendung von substituierten hydroxypiperidinen als antivirale mittel
US5462990A (en) 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
US5288931A (en) 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
EP0712635B1 (en) 1994-05-13 2003-05-02 Kuraray Co., Ltd. Medical polymer gel
WO1998009987A1 (en) 1996-09-06 1998-03-12 Biochem Pharma, Inc. Lactam inhibitors of thrombin
US6030831A (en) 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
AU3661199A (en) 1998-04-27 1999-11-16 Zymogenetics Inc. Novel polypeptide growth factors and materials and methods for making them
EP1078046A4 (en) 1998-05-12 2005-05-11 Human Genome Sciences Inc 97 HUMAN SECRETED PROTEINS
AU4643699A (en) 1998-06-24 2000-01-10 Compugen Ltd. Angiopoietin-like growth factor sequences
AU6419899A (en) 1998-10-09 2000-05-01 Regents Of The University Of Michigan, The Hydrogels and water soluble polymeric carriers for drug delivery
EP1159419A1 (en) 1999-03-08 2001-12-05 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
GB9912350D0 (en) 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
CA2375458A1 (en) 1999-07-20 2001-01-25 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20030013649A1 (en) 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
DE60141236D1 (de) 2000-10-16 2010-03-18 Genentech Inc Behandlungsverfahren unter Verwendung von WISP-Polypeptiden
US20040249141A1 (en) 2000-10-16 2004-12-09 Audrey Goddard Tie ligand homologues
EP1358163A1 (en) 2001-01-23 2003-11-05 Eli Lilly And Company Melanocortin receptor agonists
US20030027751A1 (en) 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
FI117667B (fi) 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
CA2464542C (en) 2001-11-16 2015-01-20 Genentech, Inc. Composition comprising and method of using angiopoietin-like protein 3 angptl3
RS20050202A (en) 2002-09-09 2007-08-03 Nektar Therapeuticals Al.Corporation, Water-soluble polymer alkanals
JP4685775B2 (ja) 2003-09-18 2011-05-18 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ、とりわけｈｃｖｎｓ３−ｎｓ４ａプロテアーゼの阻害剤
AU2005232371B2 (en) 2004-03-23 2010-10-14 Complex Biosystems Gmbh Polymeric prodrug with a self-immolative linker
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
EP1863340A2 (en) 2005-03-11 2007-12-12 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
JP5139271B2 (ja) 2005-05-24 2013-02-06 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ 培養した造血幹細胞を拡大しかつ分析する方法
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
WO2007003054A1 (en) 2005-07-06 2007-01-11 Shoichet Molly S Method of biomolecule immobilization on polymers using click-type chemistry
US20070060658A1 (en) 2005-08-31 2007-03-15 Diaz David D Stabilization of organogels and hydrogels by azide-alkyne [3+2] cycloaddition
ITMI20061726A1 (it) 2006-09-11 2008-03-12 Fidia Farmaceutici Derivati crosslinkati a base di acido ialuronico reticolato via click chemistry
EP2094280A1 (en) 2006-12-06 2009-09-02 Seikagaku Corporation Pharmaceutical agent having long-lasting effect of treating arthritic disorders
CN101855241B (zh) 2006-12-08 2013-11-06 莱克康制药公司 针对angptl3的单克隆抗体
WO2008097676A1 (en) 2007-02-09 2008-08-14 Irm Llc Compounds and compositions as channel activating protease inhibitors
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
MX2009010413A (es) 2007-03-29 2009-10-20 Novartis Ag 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas.
WO2008137641A2 (en) 2007-05-04 2008-11-13 Whitehead Institute For Biomedical Research Ex vivo expansion of human hematopoietic stem cells
CA2689909C (en) 2007-06-08 2016-04-05 Ascendis Pharma As Long-acting polymeric prodrugs of exendin
JPWO2009095954A1 (ja) 2008-01-31 2011-05-26 アップサイド株式会社 データ入力装置、データ入力方法ならびにデータ入力プログラムおよびこれを記録した記録媒体
US8906847B2 (en) 2008-02-01 2014-12-09 Ascendis Pharma A/S Prodrug comprising a drug linker conjugate
WO2010053861A2 (en) 2008-11-07 2010-05-14 H. Lundbeck A/S Biologically active amides
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
AU2010215196B2 (en) 2009-02-21 2015-04-16 Covidien Lp Crosslinked fibers and method of making same by extrusion
WO2010099818A1 (en) 2009-03-03 2010-09-10 Ao Technology Ag Thermoreversible polysaccharide hydrogel
WO2010102663A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Piperazine derivatives for use in therapy
IN2012DN00352A (es) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
WO2011000945A2 (en) 2009-07-03 2011-01-06 Nensius Research A/S Aminoalkamides for use in the treatment of inflammatory, degenerative or demyelinating diseases of the cns
CN105601728B (zh) 2009-07-14 2020-01-10 斯克里普斯研究所 间充质干细胞分化
JP5732053B2 (ja) 2009-07-31 2015-06-10 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 持続型インスリン組成物
WO2011012723A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Injectable sustained release compositions comprising a pramipexole prodrug
EP2459225A1 (en) 2009-07-31 2012-06-06 Ascendis Pharma A/S Carrier linked pramipexole prodrugs
WO2011012715A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Biodegradable polyethylene glycol based water-insoluble hydrogels
WO2011012722A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Prodrugs containing an aromatic amine connected by an amido bond to a linker
KR20120089843A (ko) 2009-07-31 2012-08-14 사노피-아벤티스 도이칠란트 게엠베하 인슐린 링커 접합체를 포함한 프로드럭
WO2011042450A1 (en) 2009-10-06 2011-04-14 Ascendis Pharma As Carrier linked paliperidone prodrugs
US8758780B2 (en) 2009-10-06 2014-06-24 Ascendis Pharma As Subcutaneous paliperidone composition
MX2012004499A (es) 2009-10-29 2012-05-29 Ascendis Pharma As Esterilizacion de hidrogeles biodegradables.
EP2525831B1 (en) 2010-01-22 2019-05-15 Ascendis Pharma A/S Carrier-linked carbamate prodrug linkers
EP2525829A1 (en) 2010-01-22 2012-11-28 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aromatic amine-containing drugs
DK2525830T3 (en) 2010-01-22 2016-08-15 Ascendis Pharma As DIPEPTID-BASED PRODRUG LINKERS TO ALIFATIC AMINE-CONTAINING MEDICINES
DK2563753T6 (en) 2010-04-27 2016-04-04 Synaffix Bv Fused cyclooctynforbindelser and their use in metal-free click-reactions
CN103025164B (zh) 2010-05-05 2017-03-08 普罗林科斯有限责任公司 从固体支撑物中药物的控制释放
CN103201267B (zh) 2010-07-29 2016-08-17 里格尔药品股份有限公司 Ampk-激活性杂环化合物以及其使用方法
WO2012106615A1 (en) 2011-02-03 2012-08-09 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
US9388276B2 (en) 2011-02-25 2016-07-12 University Of Massachusetts Monomers and polymers for functional polycarbonates and poly(ester-carbonates) and PEG-co-polycarbonate hydrogels
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
CZ304072B6 (cs) 2011-04-26 2013-09-25 Contipro Biotech S.R.O. Amfoterní materiál na bázi sítované kyseliny hyaluronové, zpusob jeho prípravy, materiály obsahující aktivní cinidla uzavrené v síti hyaluronanu, zpusob jejich prípravy a jejich pouzití
JPWO2012165462A1 (ja) 2011-05-31 2015-02-23 国立大学法人 東京大学 ハイドロゲル及びその製造方法
WO2012173952A1 (en) 2011-06-13 2012-12-20 Emory University Piperazine derivatives, compositions, and uses related thereto
JP2014522878A (ja) 2011-08-12 2014-09-08 アセンディス ファーマ エー／エス プロスタサイクリンの徐放組成物
CA2848142C (en) 2011-09-07 2021-05-18 Prolynx Llc Hydrogels with biodegradable crosslinking
US20130066063A1 (en) 2011-09-09 2013-03-14 John Cooke Hodges Bicyclo[6.1.0]non-4-yne regents for chemical modification of oligonucleotides
EP2765986A1 (en) 2011-10-12 2014-08-20 Ascendis Pharma Ophthalmology Division A/S Prevention and treatment of ocular conditions
US20150037311A1 (en) 2011-12-01 2015-02-05 Angiochem Inc. Targeted lysosomal enzyme compounds
JP2013116858A (ja) 2011-12-01 2013-06-13 Dainippon Sumitomo Pharma Co Ltd Ｂｄｎｆ様低分子化合物を含有する治療薬
RU2014126482A (ru) 2011-12-01 2016-01-27 Ангиочем Инк. Нацеленные соединения ферментов и их применение
JP6343604B2 (ja) 2012-05-18 2018-06-13 メディカル リサーチ カウンシル ＢＣＮ基を含むアミノ酸をコードする直交性コドンと、直交性ＰｙｌＲＳ合成酵素とを使用して、ＢＣＮ基を含むアミノ酸をポリペプチドに取り込む方法
CN104619727B (zh) 2012-06-25 2019-04-05 布里格姆及妇女医院股份有限公司 靶向治疗
KR102235868B1 (ko) * 2012-10-11 2021-04-07 아센디스 파마 옵탈몰로지 디비젼 에이/에스 안구 병태의 치료를 위한 vegf 중화 프로드럭
WO2014056926A1 (en) 2012-10-11 2014-04-17 Ascendis Pharma A/S Hydrogel prodrugs
SG11201501920PA (en) 2012-10-11 2015-04-29 Ascendis Pharma As Diagnosis, prevention and treatment of diseases of the joint
US20150267196A1 (en) 2012-10-12 2015-09-24 Case Western Reserve University Biodegradable hydrogel for polynucleotide delivery
EP2925256A4 (en) 2013-01-22 2016-08-17 Prolynx Llc SEALANTS HAVING CONTROLLED DEGRADATION
UY35368A (es) 2013-03-08 2014-10-31 Irm Llc Péptidos y composiciones para el tratamiento de daño articular
MA38369B1 (fr) 2013-03-08 2018-10-31 Novartis Ag Peptides et compositions pour le traitement d'une lesion de l'articulation
ES2701051T3 (es) 2013-03-15 2019-02-20 Novartis Ag Conjugados de anticuerpo-fármaco
CA2907830C (en) 2013-04-22 2022-03-29 Ascendis Pharma A/S Hydrogel-linked prodrugs releasing tagged drugs
EP2988732B1 (en) 2013-04-22 2023-05-03 Ascendis Pharma A/S Modified hydrogels
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
CN104292454B (zh) 2013-07-17 2017-12-01 北京键凯科技股份有限公司 聚乙二醇‑环辛炔衍生物
JP2016172783A (ja) 2013-08-08 2016-09-29 生化学工業株式会社 組織膨隆材
US20180042996A1 (en) 2013-10-08 2018-02-15 Ascendis Pharma Osteoarthritis Division A/S Hydrogel-Linked IL-1ra Prodrug
MX2016005285A (es) 2013-10-22 2016-10-28 Prolynx Llc Conjugados de somatostatina y sus analagos.
CA2929201A1 (en) 2013-11-11 2015-05-14 Ascendis Pharma Relaxin Division A/S Relaxin prodrugs
EP3110450B1 (en) 2014-02-26 2023-06-07 University of Massachusetts Medical School Degradable hydrogel with predictable tuning of properties, and compositions and methods thereof
CA2955569C (en) 2014-08-06 2023-02-14 Ascendis Pharma A/S Prodrugs comprising an aminoalkyl glycine linker
WO2016025752A1 (en) 2014-08-14 2016-02-18 Prolynx Llc Reagents for thiol conjugation and conjugates formed therefrom
TWI705827B (zh) 2014-11-07 2020-10-01 瑞士商諾華公司 治療眼部疾病之方法
SG11201705521YA (en) 2015-01-09 2017-08-30 Ascendis Pharma Growth Disorders As Cnp prodrugs
MA41794A (fr) * 2015-03-18 2018-01-23 The California Institute For Biomedical Res Agents thérapeutiques modifiés et compositions associées
WO2016196124A2 (en) 2015-05-29 2016-12-08 Ascendis Pharma Inc. Prodrugs comprising a pyroglutamate linker
EP3377047A1 (en) 2015-11-20 2018-09-26 Cristal Delivery B.V. Nanoparticles with active targeting
EP3922269A1 (en) 2016-03-16 2021-12-15 Prolynx LLC Extended release conjugates of exenatide analogs
CA3030376A1 (en) 2016-07-13 2018-01-18 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
JOP20190245A1 (ar) * 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط

Also Published As

Publication number Publication date
ZA202101419B (en) 2022-07-27
ECSP21022120A (es) 2021-04-29
CO2021004012A2 (es) 2021-04-19
CN112770782A (zh) 2021-05-07
BR112021005981A2 (pt) 2021-06-29
IL281227A (en) 2021-04-29
US20220323595A1 (en) 2022-10-13
MX2021003839A (es) 2021-05-27
JP7336513B2 (ja) 2023-08-31
CR20210156A (es) 2021-04-28
AU2019353174A1 (en) 2021-04-01
CU20210022A7 (es) 2021-10-12
US11389541B2 (en) 2022-07-19
KR20210066860A (ko) 2021-06-07
EA202190650A1 (ru) 2021-07-21
CL2021000819A1 (es) 2021-11-12
CA3112251A1 (en) 2020-04-09
PH12021550675A1 (en) 2022-01-03
JP2022501406A (ja) 2022-01-06
JOP20210061A1 (ar) 2023-01-30
EP3860657A1 (en) 2021-08-11
US20200108153A1 (en) 2020-04-09
PE20211646A1 (es) 2021-08-24
SG11202102076TA (en) 2021-04-29
WO2020070675A1 (en) 2020-04-09
JP2023145478A (ja) 2023-10-11
TW202027794A (zh) 2020-08-01
DOP2021000053A (es) 2021-04-30

Similar Documents

Publication Publication Date Title
AR116566A1 (es) Administración sostenida de polipéptidos similares a la angiopoyetina 3
AR111481A1 (es) Sistemas de entrega de liberación sostenida que comprenden enlazadores no rastreables
AR113964A1 (es) Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa
AR114254A1 (es) Moduladores del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso de preparación de los moduladores
AR110139A1 (es) COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV
AR095077A1 (es) Lípidos y composiciones lípidas para la entrega de agentes activos
AR110153A1 (es) ÁCIDOS PROPIÓNICOS 3-SUSTITUIDOS COMO INHIBIDORES DE LA INTEGRINA aV
AR114793A1 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de los mismos
AR111808A1 (es) Derivados de pirimidina como moduladores del receptor de pge2
AR096332A1 (es) Compuestos heterocíclicos tricíclicos condensados como inhibidores de la integrasa del vih
AR069045A1 (es) Derivados de amina que tienen una actividad antagonista del receptor npy y5, y sus usos
AR099367A1 (es) Inhibidores de la tirosina quinasa de bruton
AR091981A1 (es) Dihidropiridona p1 como inhibidores del factor xia
AR118826A1 (es) Inhibidores de cinasas raf
AR092306A1 (es) Antibacterianos de fenicol
AR121269A1 (es) Inhibidores de la ectonucleótido pirofosfatasa / fosfodiesterasa 1 (enpp1) y métodos de uso de los mismos
AR112283A1 (es) Uso de derivados de aminoalquilbenzotiazepina
AR062405A1 (es) Derivados de isoindol
AR120170A1 (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
AR105060A1 (es) Concentrado emulsionable que comprende un herbicida de ácido fenoxi-alcanoico
AR120169A1 (es) Derivados de 2-azaespiro[3.4]octano como agonistas de m4
AR085249A1 (es) Derivados de oxima como agonistas de gpr119
AR126733A1 (es) Inhibidores de nicotinamida ripk1
MX2018003250A (es) Moduladores no esteroideos del receptor de glucocorticoides para administración local de fármacos.
AR088761A1 (es) Inhibidores de la actividad de proteina tirosina quinasa

Legal Events

Date Code Title Description
FA Abandonment or withdrawal